Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

<p>Novel AAV-Based Approach Regenerated Myocardial Cells and Demonstrated Durable Benefit to Heart Function in Rodent Model of Chronic Cardiac Ischemic Injury SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/tenaya-therapeutics-publishes-preclinical-data-in-circulation-highlighting-the-clinical-potential-of-cellular-reprogramming-for-cardiac-regeneration/">Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>